1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care.
Crit Care Med 29:1303, 2001.
[PubMed: 11445675]
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000.
N Engl J Med 348:1546, 2003.
[PubMed: 12700374]
3. Davies AGC, Hutton J, et al: Severe sepsis—A European estimate of the burden of disease in the ICU. Paper presented at the European Society of Intensive Care Medicine Meeting, 2001.
4. Zeni F, Freeman B, Natanson C: Antiinflammatory therapies to treat sepsis and septic shock: A reassessment (editorial).
Crit Care Med 25:1095, 1997.
[PubMed: 9233726]
5. Angus DC, Kelley MA, Schmitz RJ, et al: Caring for the critically ill patient. Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease: Can we meet the requirements of an aging population?
JAMA 284:2762, 2000.
[PubMed: 11105183]
6. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.
Chest 101:1644, 1992.
[PubMed: 1303622]
7. Vincent JL: Dear SIRS, I'm sorry to say that I don't like you.
Crit Care Med 25:372, 1997.
[PubMed: 9034279]
8. Alberti C, Brun-Buisson C, Goodman SV, et al: Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients.
Am J Respir Crit Care Med 168:77, 2003.
[PubMed: 12702548]
9. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference.
Crit Care Med 31:1250, 2003.
[PubMed: 12682500]
10. O'Keefe GE, Hybki DL, Munford RS: The G → A single nucleotide polymorphism at the −308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma.
J Trauma 52:817, 2002.
[PubMed: 16548052]
11. Medzhitov R, Janeway C Jr: Innate immunity.
N Engl J Med 343:338, 2000.
[PubMed: 10922424]
12. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin.
N Engl J Med 321:280, 1989.
[PubMed: 2664516]
13. Tapper H, Herwald H: Modulation of hemostatic mechanisms in bacterial infectious diseases.
Blood 96:2329, 2000.
[PubMed: 11001879]
14. Raychaudhuri B, Abraham S, Bonfield TL, et al: Surfactant blocks lipopolysaccharide signaling by inhibiting both mitogen-activated protein and IkappaB kinases in human alveolar macrophages.
Am J Respir Cell Mol Biol 30:228, 2004.
[PubMed: 12920056]
15. Doshi SN, Marmur JD: Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 30(suppl):S241, 2002.
16. Marshall BC, Brown BR, Rothstein MA, et al: Alveolar epithelial cells express both plasminogen activator and tissue factor. Potential role in repair of lung injury. Chest 99(suppl):25S, 1991.
17. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis.
N Engl J Med 348:138, 2003.
[PubMed: 12519925]
18. Hotchkiss RS, Tinsley KW, Swanson PE, et al: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans.
J Immunol 166:6952, 2001.
[PubMed: 11359857]
19. Hotchkiss RS, Tinsley KW, Swanson PE, et al: Depletion of dendritic cells, but not macrophages, in patients with sepsis.
J Immunol 168:2493, 2002.
[PubMed: 11859143]
20. Mumford RS, Pugin J: Normal responses to inury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163:361, 2001.
21. Vervloet MG, Thijs LG, Hack CE: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.
Semin Thromb Hemost 24:33, 1998.
[PubMed: 9515778]
22. Riedemann NC, Guo RF, Neff TA, et al: Increased C5a receptor expression in sepsis.
J Clin Invest 110:101, 2002.
[PubMed: 12093893]
23. Sporn LA, Huber P: Endothelial cell biology, in Coleman RWH, Marder VJ, et al (eds): Hemostasis and Thrombosis, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001.
24. Hack CE, Zeerleder S: The endothelium in sepsis: Source of and a target for inflammation. Crit Care Med 29(suppl):S21, 2001.
25. Esmon CT: The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 5(suppl 2):S7, 2001.
26. Levi M, ten Cate H, van der Poll T: Endothelium: Interface between coagulation and inflammation. Crit Care Med 30(suppl): S220, 2002.
27. Gross PL, Aird WC: The endothelium and thrombosis.
Semin Thromb Hemost 26:463, 2000.
[PubMed: 11129402]
28. Leclerc J, Pu Q, Corseaux D, et al: A single endotoxin injection in the rabbit causes prolonged blood vessel dysfunction and a procoagulant state.
Crit Care Med 28:3672, 2000.
[PubMed: 11098972]
29. Vincent JL: Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology. Crit Care 5(suppl 2):S1, 2001.
30. Aird WC: Endothelial cell heterogeneity. Crit Care Med 31(suppl): S221, 2003.
31. Reinhart K, Bayer O, Brunkhorst F, Meisner M: Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30(suppl):S302, 2002.
32. Krafte-Jacobs B, Brilli R: Increased circulating thrombomodulin in children with septic shock.
Crit Care Med 26:933, 1998.
[PubMed: 9590325]
33. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation in severe meningococcal sepsis.
N Engl J Med 345:408, 2001.
[PubMed: 11496851]
34. de Kleijn ED, de Groot R, Hack CE, et al: Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31:1839, 2003.
35. Moss M, Gillespie MK, Ackerson L, et al: Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome.
Crit Care Med 24:1782, 1996.
[PubMed: 8917025]
36. Combes V, Simon
AC, Grau GE, et al: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.
J Clin Invest 104:93, 1999.
[PubMed: 10393703]
37. Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE: Endothelial cell apoptosis in sepsis. Crit Care Med 30(suppl):S225, 2002.
38. Fernandes CJ Jr, Akamine N, Knobel E: Cardiac troponin: A new serum marker of myocardial injury in sepsis.
Intensive Care Med 25:1165, 1999.
[PubMed: 10551977]
39. Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock.
Crit Care Clin 16:251, 2000.
[PubMed: 10768082]
40. Ruiz Bailen M: Reversible myocardial dysfunction in critically ill, noncardiac patients: A review. Crit Care Med 30:1280, 2002.
41. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock.
Circulation 75:533, 1987.
[PubMed: 3815765]
42. Parker MM, Shelhamer JH, Bacharach SL, et al: Profound but reversible myocardial depression in patients with septic shock.
Ann Intern Med 100:483, 1984.
[PubMed: 6703540]
43. Parker MM, Shelhamer JH, Natanson C, et al: Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 4:19, 1989.
44. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock.
N Engl J Med 345:588, 2001.
[PubMed: 11529214]
45. Schneider F, Lutun P, Couchot A, Bilbault P, Tempe JD. Plasma cyclic guanosine 3′-5′ monophosphate concentrations and low vascular resistance in human septic shock.
Intensive Care Med 19:99, 1993.
[PubMed: 8387555]
46. Arnalich F, Hernanz A, Jimenez M, et al: Relationship between circulating levels of
calcitonin gene-related peptide, nitric oxide metabolites and hemodynamic changes in human septic shock.
Regul Pept 65:115, 1996.
[PubMed: 8884978]
47. Martin C, Leone M, Viviand X, et al: High
adenosine plasma concentration as a prognostic index for outcome in patients with septic shock.
Crit Care Med 28:3198, 2000.
[PubMed: 11008982]
48. Taylor BS, Geller DA: Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene.
Shock 13:413, 2000.
[PubMed: 10847627]
49. Zerbe RL, Henry DP, Robertson GL:
Vasopressin response to orthostatic hypotension. Etiologic and clinical implications.
Am J Med 74:265, 1983.
[PubMed: 6824005]
50. Martin GS, Bernard GR: Airway and lung in sepsis. Intensive Care Med 27(suppl 1):S63, 2001.
51. Bannerman DD, Goldblum SE: Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol 284:L899, 2003.
52. Banna P, Marcello MF, Murabito R, et al: Ultrastructural changes of the pulmonary parenchyma after experimentally induced endotoxic shock in dogs with and without drug protection.
Respiration 47:177, 1985.
[PubMed: 3839089]
53. Whitsett JA, Weaver TE: Hydrophobic surfactant proteins in lung function and disease.
N Engl J Med 347:2141, 2002.
[PubMed: 12501227]
54. Idell S, James KK, Levin EG, et al: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.
J Clin Invest 84:695, 1989.
[PubMed: 2788176]
55. Tomashefski JF Jr: Pulmonary pathology of the adult respiratory distress syndrome.
Clin Chest Med 11:593, 1990.
[PubMed: 2268992]
56. Idell S: Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 31(suppl):S213, 2003.
57. Idell S: Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways. Crit Care Med 30(suppl):S274, 2002.
58. Gattinoni L, Vagginelli F, Chiumello D, et al: Physiologic rationale for ventilator setting in acute lung injury/acute respiratory distress syndrome patients. Crit Care Med 31(suppl):S300, 2003.
59. Gattinoni L, Pelosi P, Suter PM, et al: Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes?
Am J Respir Crit Care Med 158:3, 1998.
[PubMed: 9655699]
60. Mutlu GM, Mutlu EA, Factor P: GI complications in patients receiving mechanical ventilation.
Chest 119:1222, 2001.
[PubMed: 11296191]
61. Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301, 2000.
62. Hiltebrand LB, Krejci V, tenHoevel ME, et al: Redistribution of microcirculatory blood flow within the intestinal wall during sepsis and general anesthesia.
Anesthesiology 98:658, 2003.
[PubMed: 12606910]
63. Magnotti LJ, Upperman JS, Xu DZ, et al: Gut-derived mesenteric lymph but not portal blood increases endothelial cell permeability and promotes lung injury after hemorrhagic shock.
Ann Surg 228:518, 1998.
[PubMed: 9790341]
64. Sambol JT, Xu DZ, Adams CA, et al: Mesenteric lymph duct ligation provides long term protection against hemorrhagic shock-induced lung injury.
Shock 14:416, 2000.
[PubMed: 11028566]
65. Alverdy JC, Laughlin RS, Wu L: Influence of the critically ill state on host-pathogen interactions within the intestine: Gut-derived sepsis redefined.
Crit Care Med 31:598, 2003.
[PubMed: 12576972]
66. Gianotti L, Nelson JL, Alexander JW, et al: Post injury hypermetabolic response and magnitude of translocation: Prevention by early enteral nutrition.
Nutrition 10:225, 1994.
[PubMed: 7919674]
67. Dhainaut JF, Marin N, Mignon A, Vinsonneau C: Hepatic response to sepsis: Interaction between coagulation and inflammatory processes. Crit Care Med 29(suppl):S42, 2001.
68. Szabo G, Romics L Jr, Frendl G: Liver in sepsis and systemic inflammatory response syndrome.
Clin Liver Dis 6:1045, 2002.
[PubMed: 12516206]
69. Goyette RE: Hematology: A Comprehensive Guide to the Diagnosis and Treatment of Blood Disorders. Los Angeles, PMIC, 1997.
70. Abernethy VE, Lieberthal W: Acute renal failure in the critically ill patient.
Crit Care Clin 18:203, 2002.
[PubMed: 12053831]
71. Khan RZ, Badr KF: Endotoxin and renal function: Perspectives to the understanding of septic acute renal failure and toxic shock.
Nephrol Dial Transplant 14:814, 1999.
[PubMed: 10328448]
72. Young GB, Bolton CF, Austin TW, et al: The encephalopathy associated with septic illness.
Clin Invest Med 13:297, 1990.
[PubMed: 2078909]
73. Papadopoulos MC, Davies DC, Moss RF, et al: Pathophysiology of septic encephalopathy: A review.
Crit Care Med 28:3019, 2000.
[PubMed: 10966289]
74. Ely EW, Margolin R, Francis J, et al: Evaluation of delirium in critically ill patients: Validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
Crit Care Med 29:1370, 2001.
[PubMed: 11445689]
75. Corday E, Williams JH Jr: Effect of shock and of vasopressor drugs on the regional circulation of the brain, heart, kidney and liver.
Am J Med 29:228, 1960.
[PubMed: 13811930]
76. Ely EW, Siegel M.D., Inouye SK: Delirium in the intensive care unit: An under-recognized symptom of organ dysfunction.
Semin Respir Crit Care Med 22:115, 2001.
[PubMed: 16088667]
77. Bowton DL, Bertels NH, Prough DS, Stump DA: Cerebral blood flow is reduced in patients with sepsis syndrome.
Crit Care Med 17:399, 1989.
[PubMed: 2495896]
78. Breslow MJ, Miller CF, Parker SD, et al: Effect of vasopressors on organ blood flow during endotoxin shock in pigs. Am J Physiol 252(2 pt 2):H291, 1987.
79. Gaykema RP, Dijkstra I, Tilders FJ: Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion.
Endocrinology 136:4717, 1995.
[PubMed: 7664696]
80. Borovikova LV, Ivanova S, Zhang M, et al: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.
Nature 405:458, 2000.
[PubMed: 10839541]
81. Fleshner M, Goehler LE, Schwartz BA, et al: Thermogenic and corticosterone responses to intravenous cytokines (IL-1beta and TNF-alpha) are attenuated by subdiaphragmatic vagotomy.
J Neuroimmunol 86:134, 1998.
[PubMed: 9663558]
82. Fletcher SN, Kennedy DD, Ghosh IR, et al: Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness.
Crit Care Med 31:1012, 2003.
[PubMed: 12682465]
83. Marinelli WA, Leatherman JW: Neuromuscular disorders in the intensive care unit.
Crit Care Clin 18:915, 2002.
[PubMed: 12418447]
84. Rizoli SB, Marshall JC: Saturday night fever: Finding and controlling the source of sepsis in critical illness.
Lancet Infect Dis 2:137, 2002.
[PubMed: 11944183]
85. Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med 336:243, 1997.
[PubMed: 8995086]
86. Ely EW, Gautam S, Margolin R, et al: The impact of delirium in the intensive care unit on hospital length of stay.
Intensive Care Med 27:1892, 2001.
[PubMed: 11797025]
87. Lefcoe MS, Fox GA, Leasa DJ, et al: Accuracy of portable chest radiography in the critical care setting. Diagnosis of pneumonia based on quantitative cultures obtained from protected brush catheter.
Chest 105:885, 1994.
[PubMed: 8131557]
88. Ely EW, Haponik EF: Using the chest radiograph to determine intravascular volume status: The role of vascular pedicle width.
Chest 121:942, 2002.
[PubMed: 11888980]
89. Wheeler AP, Bernard GR: Treating patients with severe sepsis.
N Engl J Med 340:207, 1999.
[PubMed: 9895401]
90. Selberg O, Hecker H, Martin M, et al: Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6.
Crit Care Med 28:2793, 2000.
[PubMed: 10966252]
91. Luzzani A, Polati E, Dorizzi R, et al: Comparison of procalcitonin and C-reactive protein as markers of sepsis.
Crit Care Med 31:1737, 2003.
[PubMed: 12794413]
92. Wagner KE, Martinez JM, Vath SD, et al: Early immunoneutralization of
calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs.
Crit Care Med 30:2313, 2002.
[PubMed: 12394961]
93. Pettila V, Hynninen M, Takkunen O, et al: Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis.
Intensive Care Med 28:1220, 2002.
[PubMed: 12209268]
94. Wanner GA, Keel M, Steckholzer U, et al: Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients.
Crit Care Med 28:950, 2000.
[PubMed: 10809265]
95. Van der Kaay DC, De Kleijn ED, De Rijke YB, et al: Procalcitonin as a prognostic marker in meningococcal disease. Intensive Care Med 28:1606, 2002.
96. Rackow
EC, Falk JL, Fein IA, et al: Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of
albumin,
hetastarch, and saline solutions in patients with hypovolemic and septic shock.
Crit Care Med 11:839, 1983.
[PubMed: 6194934]
97. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 27:639, 1999.
98. Choi PT, Yip G, Quinonez LG, Cook DJ: Crystalloids vs. colloids in fluid resuscitation: A systematic review.
Crit Care Med 27:200, 1999.
[PubMed: 9934917]
99. Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials.
BMJ 316:961, 1998.
[PubMed: 9550953]
100. Wilkes MM, Navickis RJ: Patient survival after human
albumin administration. A meta-analysis of randomized, controlled trials.
Ann Intern Med 135:149, 2001.
[PubMed: 11487482]
101. Fink MP: Ethyl pyruvate: A novel anti-inflammatory agent. Crit Care Med 31(suppl):S51, 2003.
102. Fink MP: Ringer's ethyl pyruvate solution: A novel resuscitation fluid for the treatment of hemorrhagic shock and sepsis. J Trauma 54(suppl):S141, 2003.
103. Velasco IT, Pontieri V, Rocha e Silva M Jr, Lopes OU: Hyperosmotic NaCl and severe hemorrhagic shock. Am J Physiol 239: H664, 1980.
104. Hannemann L, Reinhart K, Korell R, et al: Hypertonic saline in stabilized hyperdynamic sepsis.
Shock 5:130, 1996.
[PubMed: 8705390]
105. Oliveria E, Weingrtner R, Oliveria ES, et al: Hemodynamic effects of a hypertonic saline solution in sepsis (abstract). Shock 6, 1996.
106. Oliveira RP, Velasco I, Soriano F, Friedman G: Clinical review: Hypertonic saline resuscitation in sepsis.
Crit Care 6:418, 2002.
[PubMed: 12398781]
107. Corso CO, Okamoto S, Leiderer R, Messmer K: Resuscitation with hypertonic saline
dextran reduces endothelial cell swelling and improves hepatic microvascular perfusion and function after hemorrhagic shock.
J Surg Res 80:210, 1998.
[PubMed: 9878316]
108. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.
N Engl J Med 340:409, 1999.
[PubMed: 9971864]
109. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med 345:1368, 2001.
[PubMed: 11794169]
110. Wu WC, Rathore SS, Wang Y, et al: Blood transfusion in elderly patients with acute myocardial infarction.
N Engl J Med 345:1230, 2001.
[PubMed: 11680442]
111. Meadows D, Edwards JD, Wilkins RG, Nightingale P: Reversal of intractable septic shock with
norepinephrine therapy.
Crit Care Med 16:663, 1988.
[PubMed: 3371042]
113. Di Giantomasso D, May CN, Bellomo R:
Norepinephrine and vital organ blood flow.
Intensive Care Med 28:1804, 2002.
114. Landry DW, Levin HR, Gallant EM, et al:
Vasopressin deficiency contributes to the vasodilation of septic shock.
Circulation 95:1122, 1997.
[PubMed: 9054839]
115. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term
vasopressin infusion during severe septic shock.
Anesthesiology 96:576, 2002.
[PubMed: 11873030]
116. Gattinoni L, Tognoni G, Pesenti A, et al: Effect of prone positioning on the survival of patients with acute respiratory failure.
N Engl J Med 345:568, 2001.
[PubMed: 11529210]
117. Slutsky AS: The acute respiratory distress syndrome, mechanical ventilation, and the prone position.
N Engl J Med 345:610, 2001.
[PubMed: 11529218]
118. Gattinoni L, Brazzi L, Pelosi P, et al: A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group.
N Engl J Med 333:1025, 1995.
[PubMed: 7675044]
119. Hayes MA, Timmins
AC, Yau EH, et al: Elevation of systemic
oxygen delivery in the treatment of critically ill patients.
N Engl J Med 330:1717, 1994.
[PubMed: 7993413]
120. MacIntyre NR, Cook DJ, Ely EW Jr, et al: Evidence-based guidelines for weaning and discontinuing ventilatory support: A collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 120(suppl):375S, 2001.
121. Ely EW, Baker AM, Dunagan DP, et al: Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously.
N Engl J Med 335:1864, 1996.
[PubMed: 8948561]
122. Ely EW, Meade MO, Haponik EF, et al: Mechanical ventilator weaning protocols driven by nonphysician health-care professionals: Evidence-based clinical practice guidelines. Chest 120(suppl):454S, 2001.
123. Jimenez MF, Marshall JC: Source control in the management of sepsis. Intensive Care Med 27(suppl 1):S49, 2001.
124. Pittet D, Thievent B, Wenzel RP, et al: Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients.
Am J Respir Crit Care Med 153:684, 1996.
[PubMed: 8564118]
125. Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
Crit Care Med 25:1115, 1997.
[PubMed: 9233735]
126. Iregui M, Ward S, Sherman G, et al: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.
Chest 122:262, 2002.
[PubMed: 12114368]
127. Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.
Am J Med 68:344, 1980.
[PubMed: 6987871]
128. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients.
Chest 115:462, 1999.
[PubMed: 10027448]
129. Bartlett JG, Dowell SF, Mandell LA, et al: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.
Clin Infect Dis 31:347, 2000.
[PubMed: 10987697]
130. Mermel LA, Farr BM, Sherertz RJ, et al: Guidelines for the management of intravascular catheter-related infections.
Clin Infect Dis 32:1249, 2001.
[PubMed: 11303260]
131. Byers K, Adal K, Anglim A, et al: Case fatality rate for catheter-related blood stream infections (CRBSI): A meta-analysis (abstract 43). Paper presented at: Proceedings of the 5th Annual Meeting of the Society for Hospital Epidemiology of America, 1995.
132. Giroir BP: An evidence-based aproach for the evaluation of new therapies for severe sepsis: Analysis of the PROWESS trial, in Balk RA (ed): Advances in the Diagnosis and Management of the Patient with Severe Sepsis. London, Royal Society of Medicine Press, 2002.
133. Group FTTFC: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 343:311, 1994.
134. Antman EM, McCabe CH, Gurfinkel EP, et al:
Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non–Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Circulation 100:1593, 1999.
[PubMed: 10517729]
135. Yan SB, Dhainaut JF: Activated protein C versus protein C in severe sepsis. Crit Care Med 29(suppl):S69, 2001.
136. Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 30(suppl):S288, 2002.
137. Schmidt-Supprian M, Murphy C, While B, et al: Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes.
Eur Cytokine Netw 11:407, 2000.
[PubMed: 11022125]
138. Grinnell BW, Hermann RB, Yan SB: Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide.
Glycobiology 4:221, 1994.
[PubMed: 7519910]
139. Cheng T, Liu D, Griffin JH, et al: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.
Nat Med 9:338, 2003.
[PubMed: 12563316]
140. Taylor FB Jr, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of
Escherichia coli infusion in the baboon.
J Clin Invest 79:918, 1987.
[PubMed: 3102560]
141. Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
Crit Care Med 29:2051, 2001.
[PubMed: 11700394]
142. Mesters RM, Helterbrand J, Utterback BG, et al: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications.
Crit Care Med 28:2209, 2000.
[PubMed: 10921542]
143. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med 344:699, 2001.
[PubMed: 11236773]
144. Angus DC, Linde-Zwirble WT, Clermont G, et al: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Crit Care Med 31:1, 2003.
[PubMed: 12544986]
145. Manns BJ, Lee H, Doig CJ, et al: An economic evaluation of activated protein C treatment for severe sepsis.
N Engl J Med 347:993, 2002.
[PubMed: 12324556]
146. Ely EW, Laterre PF, Angus DC, et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Crit Care Med 31:12, 2003.
[PubMed: 12544987]
147. Vincent JL, Angus DC, Artigas A, et al: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Crit Care Med 31:834, 2003.
[PubMed: 12626993]
148. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose
antithrombin III in severe sepsis: A randomized controlled trial.
JAMA 286:1869, 2001.
[PubMed: 11597289]
149. Hamel MB, Davis RB, Teno JM, et al: Older age, aggressiveness of care, and survival for seriously ill, hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments.
Ann Intern Med 131:721, 1999.
[PubMed: 10577294]
150. Ely EW, Wheeler AP, Thompson BT, et al: Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome.
Ann Intern Med 136:25, 2002.
[PubMed: 11777361]
151. Ely EW, Angus DC, Williams MD, et al: Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
Clin Infect Dis 37:187, 2003.
[PubMed: 12856210]
152. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis.
N Engl J Med 347:1027, 2002.
[PubMed: 12324562]
153. Angus DC, Crowther MA: Unraveling severe sepsis: Why did OPTIMIST fail and what's next?
JAMA 290:256, 2003.
[PubMed: 12851282]
154. Siegel JP: Assessing the use of activated protein C in the treatment of severe sepsis.
N Engl J Med 347:1030, 2002.
[PubMed: 12324563]
155. Ely EW, Bernard GR, Vincent JL: Activated protein C for severe sepsis.
N Engl J Med 347:1035, 2002.
[PubMed: 12324564]
156. Laterre PF, Heiselman D: Management of patients with severe sepsis, treated by drotrecogin alfa (activated). Am J Surg 184(suppl):S39, 2002.
157. Balk RA, Goyette RE: Multiple organ dysfunction syndrome in patients with severe sepsis: more than just inflammation, in Balk RA (ed): Advances in the Diagnosis and Management of the Patient with Severe Sepsis. London, Royal Society of Medicine Press, 2002.
158. Hirsh J, Warkentin TE, Shaughnessy SG, et al:
Heparin and low-molecular-weight
heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
Chest 119(suppl): 64S, 2001.
159. Inthorn D, Hoffmann JN, Hartl WH, et al: Effect of
antithrombin III supplementation on inflammatory response in patients with severe sepsis.
Shock 10:90, 1998.
[PubMed: 9721974]
160. Golino P, Ragni M, Cimmino G, Forte L: Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation.
Cardiovasc Drug Rev 20:67, 2002.
[PubMed: 12070535]
161. Enkhbaatar P, Okajima K, Murakami K, et al: Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
Am J Respir Crit Care Med 162:1752, 2000.
[PubMed: 11069808]
162. Abraham E, Reinhart K, Svoboda P, et al: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
Crit Care Med 29:2081, 2001.
[PubMed: 11700399]
163. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial.
JAMA 290:238, 2003.
[PubMed: 12851279]
164. Wiedermann CJ, Romisch J: The anti-inflammatory actions of antithrombin—A review.
Acta Med Austriaca 29:89, 2002.
[PubMed: 12168569]
165. Ahmed T, Gonzalez BJ, Danta I: Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight
heparin.
Am J Respir Crit Care Med 160:576, 1999.
[PubMed: 10430731]
167. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, et al: Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia.
Crit Care Med 31:1108, 2003.
[PubMed: 12682480]
168. Murakami K, Enkhbaatar P, Shimoda K, et al: High-dose
heparin fails to improve acute lung injury following smoke inhalation in sheep.
Clin Sci (Lond) 104:349, 2003.
[PubMed: 12653676]
169. Dhainaut JF, Yan SB, Cariou A, Mira JP: Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 30(suppl): S318, 2002.
170. Gonda Y, Hirata S, Saitoh K, et al: Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats.
Thromb Res 71:325, 1993.
[PubMed: 8236161]
171. Uchiba M, Okajima K, Murakami K, et al: Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Thromb Haemost 74:1265, 1995.
[PubMed: 8607107]
172. Nakashima M, Kanamaru M, Umemura K, Tsuruta K: Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers.
J Clin Pharmacol 38:40, 1998.
[PubMed: 9597558]
173. Welty-Wolf KE, Carraway MS, Miller DL, et al: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164(10 pt 1):1988, 2001.
174. Carraway MS, Welty-Wolf KE, Miller DL, et al: Blockade of tissue factor: treatment for organ injury in established sepsis.
Am J Respir Crit Care Med 167:1200, 2003.
[PubMed: 12714343]
175. Jilma B, Marsik C, Mayr F, et al: Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.
Clin Pharmacol Ther 72:403, 2002.
[PubMed: 12386642]
176. Abraham E, Naum C, Bandi V, et al: Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Crit Care Med 31:718, 2003.
[PubMed: 12626975]
177. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30(suppl):S294, 2002.
178. Pribbler J, Yu A, Peterman G: Evaluations of the safety, pharmacokinetics, and clinical pharmacology of recombinant human platelet activating factor acetyl hydrolase (rPAF-AH) in healthy subjects and critically ill patients. Paper presented at the 6th International Congress on PAF and Related Lipid Mediators, New Orleans, 1998.
179. Vincent JL, Spapen H, Bakker J, et al: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
Crit Care Med 28:638, 2000.
[PubMed: 10752807]
180. Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients.
N Engl J Med 348:727, 2003.
[PubMed: 12594318]
181. Carlet J: From mega to more reasonable doses of corticosteroids: A decade to recreate hope.
Crit Care Med 27:672, 1999.
[PubMed: 10321643]
182. van Leeuwen HJ, van der Bruggen T, van Asbeck BS, Boereboom FT: Effect of corticosteroids on nuclear factor-kappaB activation and hemodynamics in late septic shock. Crit Care Med 29:1074, 2001.
183. Cronin L, Cook DJ, Carlet J, et al: Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature.
Crit Care Med 23:1430, 1995.
[PubMed: 7634816]
184. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of
hydrocortisone.
Crit Care Med 26:645, 1998.
[PubMed: 9559600]
185. Annane D, Sebille V, Troche G, et al: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to
corticotropin.
JAMA 283:1038, 2000.
[PubMed: 10697064]
187. Abraham E, Evans T: Corticosteroids and septic shock.
JAMA 288:886, 2002.
[PubMed: 12186608]
188. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 29(suppl):S121, 2002.
189. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
Crit Care Med 29:765, 2001.
[PubMed: 11373466]
190. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor.
Nat Med 6:164, 2000.
[PubMed: 10655104]
191. Soriano FG, Liaudet L, Szabo E, et al: Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice.
Shock 17:286, 2002.
[PubMed: 11954828]
192. Goldfarb RD, Marton A, Szabo E, et al: Protective effect of a novel, potent inhibitor of poly(
adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis.
Crit Care Med 30:974, 2002.
[PubMed: 12006790]
193. Czermak BJ, Sarma V, Pierson CL, et al: Protective effects of C5a blockade in sepsis.
Nat Med 5:788, 1999.
[PubMed: 10395324]
194. Guo RF, Huber-Lang M, Wang X, et al: Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.
J Clin Invest 106:1271, 2000.
[PubMed: 11086028]
195. Huber-Lang MS, Sarma JV, McGuire SR, et al: Protective effects of anti-C5a peptide antibodies in experimental sepsis.
FASEB J 15:568, 2001.
[PubMed: 11259369]
196. Harris JA, Benedict FG: Biometric Study of Basal Metabolism in Man. Publication 279. Washington, DC, Carnegie Institute of Washington, 1919.
197. Perez J, Dellinger RP: Other supportive therapies in sepsis. Intensive Care Med 27(suppl 1):S116, 2001.
198. Uehara M, Plank LD, Hill GL: Components of energy expenditure in patients with severe sepsis and major trauma: A basis for clinical care.
Crit Care Med 27:1295, 1999.
[PubMed: 10446823]
199. Ackerman MH, Evans NJ, Ecklund MM: Systemic inflammatory response syndrome, sepsis, and nutritional support.
Crit Care Nurs Clin North Am 6:321, 1994.
[PubMed: 7946191]
200. Novak F, Heyland DK, Avenell A, et al:
Glutamine supplementation in serious illness: A systematic review of the evidence.
Crit Care Med 30:2022, 2002.
[PubMed: 12352035]
202. Heyland DK: Nutritional support in the critically ill patients. A critical review of the evidence.
Crit Care Clin 14:423, 1998.
[PubMed: 9700440]
203. Atkinson S, Sieffert E, Bihari D: A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Guy's Hospital Intensive Care Group.
Crit Care Med 26:1164, 1998.
[PubMed: 9671364]
204. Gadek JE, DeMichele SJ, Karlstad MD, et al: Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group.
Crit Care Med 27:1409, 1999.
[PubMed: 10470743]
205. Heyland DK, MacDonald S, Keefe L, Drover JW: Total parenteral nutrition in the critically ill patient: A meta-analysis.
JAMA 280:2013, 1998.
[PubMed: 9863853]
206. Fan J, Li YH, Wojnar MM, Lang CH: Endotoxin-induced alterations in insulin-stimulated phosphorylation of
insulin receptor, IRS-1, and MAP kinase in skeletal muscle.
Shock 6:164, 1996.
[PubMed: 8885080]
207. Youd JM, Rattigan S, Clark MG: Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha.
Diabetes 49:1904, 2000.
[PubMed: 11078458]
208. Rosmarin DK, Wardlaw GM, Mirtallo J: Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition
dextrose.
Nutr Clin Pract 11:151, 1996.
[PubMed: 9070016]
209. Fietsam R Jr, Bassett J, Glover JL: Complications of coronary artery surgery in diabetic patients.
Am Surg 57:551, 1991.
[PubMed: 1928997]
210. Khaodhiar L, McCowen K, Bistrian B: Perioperative hyperglycemia, infection or risk?
Curr Opin Clin Nutr Metab Care 2:79, 1999.
[PubMed: 10453334]
211. Kwoun MO, Ling PR, Lydon E, et al: Immunologic effects of acute hyperglycemia in nondiabetic rats.
JPEN 21:91, 1997.
[PubMed: 9084011]
212. Rao AK, Chouhan V, Chen X, et al: Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.
Diabetes 48:1156, 1999.
[PubMed: 10331423]
213. Boeri D, Almus FE, Maiello M, et al: Modification of tissue-factor mRNA and protein response to
thrombin and interleukin 1 by high glucose in cultured human endothelial cells.
Diabetes 38:212, 1989.
[PubMed: 2783675]
214. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.
Circulation 99:2626, 1999.
[PubMed: 10338454]
215. Malmberg K: Prospective randomised study of intensive
insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus,
Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.
BMJ 314:1512, 1997.
[PubMed: 9169397]
216. van den Berghe G, Wouters P, Weekers F, et al: Intensive
insulin therapy in the critically ill patients.
N Engl J Med 345:1359, 2001.
217. Van den Berghe G, Wouters PJ, Bouillon R, et al: Outcome benefit of intensive
insulin therapy in the critically ill:
Insulin dose versus glycemic control.
Crit Care Med 31:359, 2003.
218. Finney SJ, Zekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients.
JAMA 290:2041, 2003.
[PubMed: 14559958]
219. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis.
JAMA 275:1489, 1996.
[PubMed: 8622223]
220. Chertow GM, Levy EM, Hammermeister KE, et al: Independent association between acute renal failure and mortality following cardiac surgery.
Am J Med 104:343, 1998.
[PubMed: 9576407]
221. Bellomo R, Chapman M, Finfer S, et al: Low-dose
dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group.
Lancet 356:2139, 2000.
[PubMed: 11191541]
222. Meyer MM: Renal replacement therapies.
Crit Care Clin 16:29, 2000.
[PubMed: 10650499]
223. Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure.
N Engl J Med 346:305, 2002.
[PubMed: 11821506]
224. Cade JF: High risk of the critically ill for venous thromboembolism.
Crit Care Med 10:448, 1982.
[PubMed: 7044682]
225. Hirsch DR, Ingenito EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care.
JAMA 274:335, 1995.
[PubMed: 7609264]
226. Jorgensen LN, Wille-Jorgensen P, Hauch O: Prophylaxis of postoperative thromboembolism with low molecular weight heparins.
Br J Surg 80:689, 1993.
[PubMed: 7687188]
227. Bauer KA, Eriksson BI, Lassen MR, Turpie AG:
Fondaparinux compared with
enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
N Engl J Med 345:1305, 2001.
[PubMed: 11794149]
228. Eriksson BI, Bauer KA, Lassen MR, Turpie AG:
Fondaparinux compared with
enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
N Engl J Med 345:1298, 2001.
[PubMed: 11794148]
229. Cook DJ, Fuller HD, Guyatt GH, et al: Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.
N Engl J Med 330:377, 1994.
[PubMed: 8284001]
230. Schuster DP, Rowley H, Feinstein S, et al: Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit.
Am J Med 76:623, 1984.
[PubMed: 6608877]
231. Cook D, Guyatt G, Marshall J, et al: A comparison of
sucralfate and
ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group.
N Engl J Med 338:791, 1998.
[PubMed: 9504939]
232. Prod'hom G, Leuenberger P, Koerfer J, et al: Nosocomial pneumonia in mechanically ventilated patients receiving antacid,
ranitidine, or
sucralfate as prophylaxis for stress ulcer. A randomized controlled trial.
Ann Intern Med 120:653, 1994.
[PubMed: 16543580]
233. Yan SB, Helterbrand JD, Hartman DL, et al: Low levels of protein C are associated with poor outcome in severe sepsis.
Chest 120:915, 2001.
[PubMed: 11555529]
234. Taylor FB Jr, Toh CH, Hoots WK, et al: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.
Thromb Haemost 86:1327, 2001.
[PubMed: 11816725]
235. Feinstein DI: Diagnosis and management of disseminated intravascular coagulation: The role of
heparin therapy.
Blood 60:284, 1982.
[PubMed: 7046845]
236. Aoki N, Matsuda T, Saito H, et al: A comparative double-blind randomized trial of activated protein C and unfractionated
heparin in the treatment of disseminated intravascular coagulation.
Int J Hematol 75:540, 2002.
[PubMed: 12095157]
237. Joyce D, Yan B, Basson BR, et al: Disseminated intravascular coagulation in severe sepsis patients treated with recombinant human activated protein C (abstract). Blood 98:445a, 2001.
238. Lemeshow S, Klar J, Teres D: Outcome prediction for individual intensive care patients: Useful, misused, or abused?
Intensive Care Med 21:770, 1995.
[PubMed: 8847434]
239. Cowen JS, Kelley MA: Errors and bias in using predictive scoring systems.
Crit Care Clin 10:53, 1994.
[PubMed: 8118733]
240. Escarce JJ, Kelley MA: Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score.
JAMA 264:2389, 1990.
[PubMed: 2231994]
241. Vincent JL, de Mendonca A, Cantraine F, et al: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine.
Crit Care Med 26:1793, 1998.
[PubMed: 9824069]
242. Hebert PC, Drummond AJ, Singer J, et al: A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome.
Chest 104:230, 1993.
[PubMed: 8325076]